VEA
KROS icon

Virtus ETF Advisers’s Keros Therapeutics KROS Stock Holding History

Virtus ETF Advisers’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,857
Closed -$61.1K – 621
2024
Q4 		$61.1K Buy
3,857
+1,998
+107% +$104K 0.02% 446
2024
Q3 		$108K Buy
1,859
+30
+2% +$1.48K 0.05% 365
2024
Q2 		$83.6K Sell
1,829
-738
-29% -$39.7K 0.04% 386
2024
Q1 		$170K Sell
2,567
-176
-6% -$10.4K 0.09% 305
2023
Q4 		$109K Buy
2,743
+182
+7% +$5.71K 0.07% 332
2023
Q3 		$81.6K Sell
2,561
-257
-9% -$9.59K 0.05% 357
2023
Q2 		$113K Buy
2,818
+801
+40% +$35.1K 0.07% 336
2023
Q1 		$86.1K Sell
2,017
-771
-28% -$38.9K 0.05% 373
2022
Q4 		$134K Sell
2,788
-1,037
-27% -$48.4K 0.07% 382
2022
Q3 		$144K Buy
3,825
+32
+0.8% +$1.11K 0.06% 359
2022
Q2 		$105K Buy
3,793
+568
+18% +$24.9K 0.04% 420
2022
Q1 		$175K Sell
3,225
-191
-6% -$9.8K 0.08% 208
2021
Q4 		$200K Sell
3,416
-600
-15% -$29.9K 0.08% 209
2021
Q3 		$159K Sell
4,016
-213
-5% -$7.58K 0.07% 328
2021
Q2 		$180K Buy
4,229
+394
+10% +$21.3K 0.07% 386
2021
Q1 		$236K Buy
3,835
+77
+2% +$4.88K 0.1% 299
2020
Q4 		$265K Buy
+3,758
New +$237K 0.11% 290

Other funds holding KROS

Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Virtus ETF Advisers's KROS Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 3,857 shares — an estimated $61.1K sold.

Virtus ETF Advisers first reported a position in KROS in Q4 2020 and held it in 17 quarters. The position peaked at $265K in Q4 2020. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 3,857 Keros Therapeutics shares in Q1 2025, an estimated $61.1K.
  • Virtus ETF Advisers first reported a position in Keros Therapeutics in Q4 2020 and held it in 17 quarters.
  • Virtus ETF Advisers's Keros Therapeutics position peaked at $265K in Q4 2020.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.